Nasodren Scientific support
In March, another unique and impressive study was accepted for publication in The Laryngoscope, (organ of the American Laryngological, Rhinological and Otological Society): “An exploratory Trial of Cyclamen Europaeum Extract for Acute Rhinosinusitis” by J. Ponikau et al.
The key messages learnt from this study are:
In patients with Acute Rhinosinusitis, Cyclamen extract (Nasodren:
- Improves objective outcomes compared to placebo
- Produces a clinically relevant symptoms improvement
- Is the only product marketed for Rhinosinusitis that has been tested in this way (CT); other products, such as corticosteroids, antibiotics or decongestants, measure only symptomatic improvement.
The results of these studies have led, as mentioned above, to the inclusion of Cyclamen europaeum, in the EPOS 2012, the European Guidelines on Rhinosinusitis. Therefore, we can claim to possess a unique product for the treatment of this prevalent condition.
References:
Pfaar O, Mullol J, Anders C, Hormann K, Klimek L. Cyclamen europaeum nasal spray, a novel phytotherapeutic product for the management of acute Rhinosinusitis: a randomized double-blind, placebo-controlled trial. Rhinology. 2012 Mar;50(1):37-44. PMID: 22469604
Ponikau J, Hamilos D, Barreto A, Cecil J, Jones S, Manthei S. An exploratory trial of Cyclamen europaeum extract for acute Rhinosinusitis. Accepted for publication Laryngoscope, March, 2012. PMID: 22675486
